NIH launches trial of Rigel drug for severe COVID-19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Rigel Pharmaceuticals (RIGL) COVID-19 Treatment Could Be Potential Catalyst - BMO
September 17, 2020 10:04 AM EDTBMO Capital analyst Do Kim reiterated an Outperform rating and $8.00 price target on Rigel Pharmaceuticals (NASDAQ: RIGL) after the NIH initiated a Phase 2 study evaluating Tavalisse in hospitalized COVID-19 patients. Patients will receive treatment for 14 days and have a 60-day follow-up period.
"We... More
